Cancer Diagnostics Market
Market Insights on Cancer Diagnostics covering sales outlook, demand forecast & up-to-date key trends
Cancer Diagnostics Market by Test Type (Tumour Biomarkers Tests, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), End-user & Region - Forecast to 2021-2031
Cancer Diagnostics Market - About the Report
[285 Pages Report] The rising prevalence of cancers has necessitated innovation in the cancer diagnostics. The global market is set to grow at an impressive pace over forecast period. Use of advanced technologies such as liquid biopsy for breast cancer, prostate cancer and lung cancer diagnosis and treatment can result in favorable therapeutic outcomes. Furthermore, the increasing advancements in imaging technologies for early-stage diagnosis of cancer is expected to boost the market for cancer diagnostics.
In its latest edition of the study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for cancer diagnostics. The report tracks the global sales of cancer diagnostics in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on cancer diagnosis services in general, and cancer diagnostics in particular.
Let us know your requirement to get
100% FREE customization
How Historical and Future Outlook for Cancer Diagnostics Market Match Up?
As per the World Health Organization (WHO), in 2020 around 19 Mn new cancer cases were diagnosed across the world. Likewise, the American Cancer Society reported that the 89,500 cases of cancer were diagnosed in U.S. in 2020. The most common cancers in the U.S. include lung cancer, breast cancer, prostate cancer, colorectal cancer, thyroid cancer, pancreatic cancer, non-Hodgkin lymphoma, melanoma, endometrial cancer, renal pelvis cancer, kidney cancer and leukemia.
Governments in developed countries such as the U.S. raise funds for cancer research to aid in the diagnosis and treatment. They also are funding clinical trials to support companies in developing effective diagnostic tests for cancer. According to the American Association for Cancer Research, Cancer Epidemiology, Biomarkers & Prevention journal reported that national cancer-attributable costs in the United States are projected to increase by over 30 % from 2015 to 2030, corresponding to a total cost of over $245 billion.
Late diagnosis of cancer is the chief reason behind the rising mortality rates. This has been fuelling the demand for improvement in screening and diagnosis. Moreover, investments in the field of research is estimated to create new opportunities for the cancer diagnostics market in the coming years. Research funding from governments and improving reimbursement facilities for cancer diagnostics are expected to boost the market.
In 2019, the American Cancer Society has funded more than $67 million in breast cancer research through 162 research and training grants. Likewise, the increased funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) by the American Cancer Society Cancer Action Network (ACS CAN), at the state and federal levels.
Similarly constantly evolving technology such as next-generation sequencing techniques for cancer diagnostics and patient-based cancer diagnostics would fuel the demand for cancer diagnostics. Next-generation sequencing (NGS) is the most cost-effective, time-saving and successful technological advances in cancer diagnostics in the last 3 decades. Revolutionary second-generation and third platforms offered by Roche, Illumina and Life Technologies, Pacific Biosciences of California, Inc. are rapidly gaining absorbed in the market. Many molecular pathology laboratories are transitioning from single molecular PCR protocols to adopt NGS platforms, and thus the market for cancer diagnostic is expected to gain traction.
According to FMI’s analysis, cancer diagnostics sales have grown at an 8.5% CAGR between 2021 and 2031. The cancer diagnostics market experienced a short-term negative impact owing to a sharp reduction in the number of patients in hospitals for cancer diagnosis across the world. The market is expected to recover by mid-2021. As the COVID-19 cases were rising, the healthcare system had shifted its focus towards mitigating the ongoing global medical emergency.
The screening of cancer, case identification, and referral in symptomatic cancer diagnosis is declined due to the outbreak of COVID-19. Even the follow-up and management of cancer patients are also exaggerated by the pandemic. For instance, a 40% decline in weekly cancer incidence is reported by Netherlands Cancer Registry in 2020, and the U.K. has accomplished a 75% decline in referrals for assumed cancer since the onset of COVID-19.? However, in the coming years, a significant increase is projected in cancer diagnostic procedures.
FMI expects the global cancer diagnostics market to grow at 8.5% CAGR through 2031.
How is Shift towards Advanced Diagnostics Fuelling Cancer Diagnostics Demand?
Advances in diagnostics such as imaging techniques have increased the demand for cancer diagnostics. Imaging has become an important aspect of cancer detection and diagnosis and recent progress in tumour imaging technologies have improved the diagnosis of 5 common cancers including cancers of breast, lung, prostate and colorectal cancers. For instance, in 2018 ultrasound technology MicroPure was introduced by Toshiba Medical Systems Corporation for the early detection of microcalcification in breast tissue. With the growing preferences for PET cameras, the technology has gone through several evolutions resulting in cutting down the time for image processing. Similarly, the addition of PET/CT enabled the acquisition of morphological and functional information simultaneously.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat Are The Opportunities In The Cancer Diagnostics Market?
Increasing patient acceptance for non-invasive tests & hospital laboratory needs presents huge growth opportunities for developers and manufacturers of cancer diagnostic tests. Due to healthcare cost containment in the majority of mature markets, hospital-based laboratories are facing pressure to supply more services at a reduced cost. Healthcare facilities are faced with challenges related to increasing ageing population and a rising prevalence of chronic diseases.
By 2018, almost 10% of the global population will be 65 & above. Also, global healthcare spending is expected to witness a 5.2% growth every year till 2018. This imposes cost management pressure on diagnostic labs. Thus, a majority of laboratories have started adapting informatics solutions which helps them to increase overall productivity with existing resources. In line with this, manufacturers of diagnostic tests can grab the opportunity to provide complementary services and support.
For instance, in 2016 Abbott laboratories launched AlinIQ support and services to help their laboratory partners accomplish maximize output and capacity during operations. Similarly, bioMérieux’s LEAN lab assessment program is witnessing to increase labs’ productivity by up to 30%. There is a growing concern in the development of newer and sensitive techniques to diagnose cancer patients as early as possible, especially in high-risk groups where conventional technology falls short, thus creating opportunities in the cancer diagnostics market.
What is the Potential of Imaging Technique?
Imaging helps in the better staging of cancer, along with prognostic and treatment monitoring capabilities of functional and metabolic information. Owing to these benefits, the application of imaging techniques has fundamentally increased in cancer screening programs. The adoption of advanced imaging tests such as multiphoton microscopy and magnetic resonance imaging is growing across the world.
This technology shortens acquisition time and fusion imaging by providing precise attenuation modification, and, leading to an increase in diagnostic specificity and sensitivity imaging, thus plays an important role in staging, initial diagnosis, and monitoring of treatment response. Implementation of diagnostic imaging processes will be supplementary reorganized by multimodality imaging techniques, due to their use in the improvement of a specific treatment plan for custom-made cancer treatment.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
What Is The Regulatory Impact On Cancer Diagnostics?
Insufficient insurance coverage for costly cancer diagnostics tests is the major factor hampering the growth of the global cancer diagnostics market. Despite high-value propositions of molecular diagnostics for cancer, insufficient coverage for costly test procedures discourage a large section of patients from pursuing these tests.
Furthermore, as per the new pricing policy for 2017, CMS has increased rates for numerous new CPT codes including next-generation sequencing and multi-analyte algorithm assays. For instance, CMS increased the cost of next-generation sequencing tests for genetic breast cancer (CPT code 81432) from US$ 623 to US$ 925. It is expected that state Medicaid programs will also adjust their prices to reflect Medicare rates. Regulators of CMS, as well as private payers, are progressively highlighting the growing value and single-source tests having strong evidence of clinical utility.
Development of analytical instruments used for laboratory analysis of cancer specimen and high-end instruments such as MRI, PET, SPECT equipment and next-generation sequencing platforms requires high investment in terms of both money and time. While this might discourage smaller players, some of the big pharmaceutical companies are entering into the diagnostics business.
If at all the company develops innovative diagnostic testing, they still have to invest in special clinical efficacy studies, and there is no assurance that the product will get coverage. This might create obstacles to growth.
What Are Key Trends In Cancer Diagnostics Market?
An increasing number of the key players in the cancer diagnostics market are implementing inert growth strategies to sustain in the growing competitive burden. Companies in the global market are enthusiastically involved in mergers and acquisitions, as the industry is in its growth phase as of continuous technology upgrades and the launch of novel blood tests to detect cancer.
Players in the liquid biopsy industry have started taking strategic decisions to occupy in strategic partnerships and collaborations to support their product portfolio and surge their brand share in the market. Thus, these companies have strengthened their positions in the cancer diagnostics market.
For instance, in March 2021, Agilent Technologies Inc. acquired Resolution Bioscience, to reinforce its headship position in cancer diagnostics and in September 2020, Illumina, Inc. acquired GRAIL to launch a new phase of a cancer diagnosis. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosis test with the prospective to detect more cancers earlier and enable better outcomes.
Cancer Diagnostics Market - Country-wise Insights
Why is Demand for Cancer Diagnostics High in the U.S.?
The rising prevalence of cancer in the U.S. is likely to boost cancer diagnostics demand. Cancer is the second-leading cause of death in the United States. In 2020, there will be approximately 89,500 cancer cases diagnosed and around 9,300 cancer deaths in adolescents and young adults (AYAs) aged 15 to 39 years, in the US.
Moreover, the U.S. is considered the largest market for medical devices in the world, which invariably makes it a lucrative pocket for cancer diagnostics. According to SelectUSA, the medical devices market in the U.S. accounted for 40% of the global market in 2017. By 2023, it is expected to reach US$ 203 billion in valuation.
Favorable healthcare policies, coupled with high per capita healthcare spending, has created a conducive environment for the adoption of advanced cancer diagnostic technologies such as imaging in the U.S. Also, the presence of leading players is supporting growth in the U.S. Strategies undertaken by these companies include product launches and expansion plans, which will continue aiding overall expansion in the U.S.
What Are the Factors Hampering Cancer Diagnostics in South Africa?
Lack of awareness about advance cancer screening tests and insufficient treatment options leads to increasing incidence of cancer. Due to limited campaigning about the assessment of these cancers, there seems to occur minimum practice of this cancer diagnosis tests in hospitals in South Africa. Additionally, inadequate healthcare services in South Africa as compared to the developed countries is hindering the growth of the cancer diagnostics market in South Africa.
Other factors responsible for the hindrance of cancer diagnostics services in South Africa are a financial burden, governments fail to provide proper screening and diagnosis for cancer patients and are unable to facilitate campaigns to create awareness among the population, which may impact the adoption of cancer diagnostics in this region. The market in South Africa is expected to witness sluggish growth with a revenue share of around 22% at the end of 2031.
What Is Driving Adoption Of Cancer Diagnostics In China?
Growth in East Asia is expected to happen at a faster speed. The World Health Organization has reported that in 2020, about 4.5 Mn new cancer cases are diagnosed in China. The incidence rate of obesity and hormonal exposure-related cancers, like breast cancer in females and “lifestyle change-related cancer”, such as prostate cancer in males, showed a rising trend in China which results in surging adoption of cancer diagnostics in China.
Based on results revealed in the Global Burden of Disease Study, cancer is the leading cause of death in the country in 2020. These figures are indicative of opportunities for wider penetration in China, consequently in South Asia. An increase in the incidences of cancer and increasing awareness related to early detection of cancer in Asian countries such as China is another key factor driving rapid growth in the market.
Cancer Diagnostics Market - Category-wise Insights
Why is Demand for Liquid Biopsy High?
Liquid biopsies are developing as a promising alternative to conventional biopsies, due to their noninvasiveness for the diagnosis and monitoring of cancers. Current technological advances in the liquid biopsy potential to address the current limitations of biopsies and increase the sensitivity of cancer diagnosis are results in the highest revenue in the cancer diagnostics market.
Which is the Key Indication for Cancer Diagnostics?
In terms of indication, cancer diagnostics is being resorted primarily for lung cancer diagnosis. According to the American Lung Association, approximately 541,000 Americans are living with lung cancer. According to the World Health Organization, lung cancer has caused nearly 2.21 million deaths in 2020. With the incidence of the ailment projected to increase, the demand for accurate and timely diagnosis is expected to rise.
Who is the Leading End User?
Hospital associated labs have emerged as the leading end user. Besides the higher footfall of patients, access to advanced infrastructure and modern medical tools support expansion of the segment.
Cancer Diagnostics Market - Competitive Landscape
Most of the medical device companies are currently focusing on developing advanced diagnostic tests for assessment of cancer screening.
For example, in December 2020, Philips has introduced its latest advancements in digital pathology to boosts digital pathology with enhanced informatics to advance precision diagnosis in cancer diagnosis.
Moreover, the manufactures are focusing on getting stamp of approvals for their product and also entering into partnership and collaboration agreement to expand their product portfolio in different countries globally.
For instance, in February 2021, Agilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC).
Some of the leading companies operating in the market are:
- Abbott Laboratories
- Roche
- Thermo Fisher Scientific Inc.
- Siemens AG
- Bio Rad Laboratories Inc.
- Illumina, Inc.
- Koninklijke Philips N.V.
- Canon Medical Systems Corporation
- Agilent Technologies Inc.
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Cancer Diagnostics Market - Scope of the Report
|
Attribute |
Details |
|
Cancer Diagnostics Market Forecast Period |
2021-2031 |
|
Cancer Diagnostics Market - Historical Data Available for |
2016-2020 |
|
Cancer Diagnostics Market - Market Analysis |
USD Million for Value |
|
Cancer Diagnostics Market- Key Regions Covered |
North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa |
|
Cancer Diagnostics Market - Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
|
Cancer Diagnostics Market - Key Segments Covered |
Test Type, Indication, End-user and Region |
| Key Companies Profiled |
|
|
Cancer Diagnostics Market- Report Coverage |
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
|
Customization & Pricing |
Cancer Diagnostics Market by Category
Test Type
- Tumour Biomarkers Tests
- PSA Tests
- CTC Tests
- AFP Tests
- CA Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Others
- Imaging
- Ultrasound
- Mammography
- MRI Scan
- PET Scan
- CT Scan
- SPECT & Others
- Biopsy
- Needle Biopsy
- Endoscopic Biopsy
- Bone Marrow Biopsy
- Others
- Liquid Biopsy
- Immunohistochemistry
- In Situ Hybridization
Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Blood Cancer
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
- Others
End-user
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
Frequently Asked Questions
The US currently leads the North America market for cancer diagnostics. Sales in the US will account for over 85% of total demand in North America throughout the forecast period.
Liquid Biopsy is in high demand in terms of test type. This is because of its ease of operability and noninvasiveness.
Hospitals associated labs have emerged as leading the end user in the cancer diagnostics market.
Some of the leading players operating in the cancer diagnostics market are Abbott Laboratories, Roche, Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., Illumina, Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, and Agilent Technologies Inc. among others
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Market Dynamics
2.4. Inclusions and Exclusions
3. Market Background
3.1. Macro-Economic Factors
3.1.1. Global GDP Growth Outlook
3.1.2. Global Healthcare Expenditure Outlook
3.1.3. Growth of Healthcare Sector in Emerging Nations
3.2. Forecast Factors - Relevance & Impact
3.2.1. Global Increase in Healthcare Expenditure
3.2.2. Rising Prevalence of Cancer
3.2.3. Changing Regulatory Dynamics
3.2.4. Cost Impact
3.2.5. Regulatory Scenario
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunity Analysis
4. Market Context
4.1. Key Industry Developments
4.2. Disease Epidemiology
4.3. Regulatory and Reimbursement Scenario
4.4. Strategic Promotional Strategies by Manufacturer
5. COVID19 Crisis Impact Analysis
5.1.1. Current perspectives on the Coronavirus outbreak
5.1.2. Current GDP Projection and Probable Impact
5.1.3. Current Economic Projection as compared to 2008 Economic analysis
5.1.4. COVID19 and Impact Analysis
5.2. Cancer Diagnostics Market Revenue Impact Analysis
5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
5.2.1.1. By Test Type
5.2.1.2. By Indication
5.2.1.3. By End User
5.2.1.4. By Region
5.2.2. 2020 Market Scenario
5.3. Impact on Trends Analysis
5.4. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Global Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast, 2021–2031
6.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
6.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, By Test Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Test Type, 2016 - 2020
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Test Type, 2021 - 2031
7.3.1. Tumor Biomarkers Tests
7.3.1.1. PSA Tests
7.3.1.2. CTC Tests
7.3.1.3. AFP Tests
7.3.1.4. CA Tests
7.3.1.5. HER2 Tests
7.3.1.6. BRCA Tests
7.3.1.7. ALK Tests
7.3.1.8. CEA Tests
7.3.1.9. EGFR Mutation Tests
7.3.1.10. KRAS Mutation Tests
7.3.1.11. Others
7.3.2. Imaging
7.3.2.1. Ultrasound
7.3.2.2. Mammography
7.3.2.3. MRI Scan
7.3.2.4. PET Scan
7.3.2.5. CT Scan
7.3.2.6. SPECT & Others
7.3.3. Biopsy
7.3.3.1. Needle Biopsy
7.3.3.2. Endoscopic Biopsy
7.3.3.3. Bone Marrow Biopsy
7.3.3.4. Others
7.3.4. Liquid Biopsy
7.3.5. Immunohistochemistry
7.3.6. In Situ Hybridization
7.4. Market Attractiveness Analysis By Test Type
8. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2016 - 2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2021 - 2031
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Melanoma
8.3.5. Blood Cancer
8.3.6. Prostate Cancer
8.3.7. Ovarian Cancer
8.3.8. Stomach Cancer
8.3.9. Liver Cancer
8.3.10. Others
8.4. Market Attractiveness Analysis By Indication
9. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016 - 2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021 - 2031
9.3.1. Hospital Associated Labs
9.3.2. Independent Diagnostic Laboratories
9.3.3. Diagnostic Imaging Centers
9.3.4. Cancer Research Institutes
9.3.5. Others
9.4. Market Attractiveness Analysis By End User
10. Global Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 - 2020
10.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
11.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Test Type
11.3.3. By Indication
11.3.4. By End User
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
12.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Test Type
12.3.3. By Indication
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
13.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Test Type
13.3.3. By Indication
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. South Asia Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
14.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Test Type
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. East Asia Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
15.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Test Type
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Oceania Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
16.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Test Type
16.3.3. By Indication
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Middle East and Africa Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016 - 2020
17.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. South Africa
17.3.1.3. Rest of Middle East and Africa
17.3.2. By Test Type
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Key and Emerging Countries Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. U.S. Cancer Diagnostics Market Analysis
18.2.1. By Test Type
18.2.2. By Indication
18.2.3. By End User
18.3. Canada Cancer Diagnostics Market Analysis
18.3.1. By Test Type
18.3.2. By Indication
18.3.3. By End User
18.4. Mexico Cancer Diagnostics Market Analysis
18.4.1. By Test Type
18.4.2. By Indication
18.4.3. By End User
18.5. Brazil Cancer Diagnostics Market Analysis
18.5.1. By Test Type
18.5.2. By Application
18.5.3. By Indication
18.5.4. By End User
18.6. U.K. Cancer Diagnostics Market Analysis
18.6.1. By Test Type
18.6.2. By Indication
18.6.3. By End User
18.7. Germany Cancer Diagnostics Market Analysis
18.7.1. By Test Type
18.7.2. By Indication
18.7.3. By End User
18.8. France Cancer Diagnostics Market Analysis
18.8.1. By Test Type
18.8.2. By Indication
18.8.3. By End User
18.9. Italy Cancer Diagnostics Market Analysis
18.9.1. By Test Type
18.9.2. By Indication
18.9.3. By End User
18.10. France Cancer Diagnostics Market Analysis
18.10.1. By Test Type
18.10.2. By Indication
18.10.3. By End User
18.11. Spain Cancer Diagnostics Market Analysis
18.11.1. By Test Type
18.11.2. By Indication
18.11.3. By End User
18.12. Russia Cancer Diagnostics Market Analysis
18.12.1. By Test Type
18.12.2. By Indication
18.12.3. By End User
18.13. Poland Cancer Diagnostics Market Analysis
18.13.1. By Test Type
18.13.2. By Indication
18.13.3. By End User
18.14. China Cancer Diagnostics Market Analysis
18.14.1. By Test Type
18.14.2. By Indication
18.14.3. By End User
18.15. Japan Cancer Diagnostics Market Analysis
18.15.1. By Test Type
18.15.2. By Indication
18.15.3. By End User
18.16. South Korea Cancer Diagnostics Market Analysis
18.16.1. By Test Type
18.16.2. By Indication
18.16.3. By End User
18.17. India Cancer Diagnostics Market Analysis
18.17.1. By Test Type
18.17.2. By Indication
18.17.3. By End User
18.18. Thailand Cancer Diagnostics Market Analysis
18.18.1. By Test Type
18.18.2. By Indication
18.18.3. By End User
18.19. Indonesia Cancer Diagnostics Market Analysis
18.19.1. By Test Type
18.19.2. By Indication
18.19.3. By End User
18.20. Malaysia Cancer Diagnostics Market Analysis
18.20.1. By Test Type
18.20.2. By Indication
18.20.3. By End User
18.21. Australia Cancer Diagnostics Market Analysis
18.21.1. By Test Type
18.21.2. By Indication
18.21.3. By End User
18.22. New Zealand Cancer Diagnostics Market Analysis
18.22.1. By Test Type
18.22.2. By Indication
18.22.3. By End User
18.23. GCC Countries Cancer Diagnostics Market Analysis
18.23.1. By Test Type
18.23.2. By Indication
18.23.3. By End User
18.24. Turkey Cancer Diagnostics Market Analysis
18.24.1. By Test Type
18.24.2. By Indication
18.24.3. By End User
18.25. South Africa Cancer Diagnostics Market Analysis
18.25.1. By Test Type
18.25.2. By Indication
18.25.3. By End User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Concentration
19.4. Competition Benchmarking
19.5. Market Presence Analysis
19.5.1. Regional Footprint by Players
19.5.2. Product Foot print by Players
19.5.3. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive (Tentative List)
20.2.1. Abbott Laboratories
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Profitability by Market Segments (Product/Channel/Region)
20.2.1.4. Sales Footprint
20.2.1.5. Strategy Overview
20.2.1.5.1. Marketing Strategy
20.2.1.5.2. Product Strategy
20.2.1.5.3. Channel Strategy
20.2.2. Roche Holding AG
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. Profitability by Market Segments (Product/Channel/Region)
20.2.2.4. Sales Footprint
20.2.2.5. Strategy Overview
20.2.2.5.1. Marketing Strategy
20.2.2.5.2. Product Strategy
20.2.2.5.3. Channel Strategy
20.2.3. Thermo Fisher Scientific Inc.
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. Profitability by Market Segments (Product/Channel/Region)
20.2.3.4. Sales Footprint
20.2.3.5. Strategy Overview
20.2.3.5.1. Marketing Strategy
20.2.3.5.2. Product Strategy
20.2.3.5.3. Channel Strategy
20.2.4. Siemens AG
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. Profitability by Market Segments (Product/Channel/Region)
20.2.4.4. Sales Footprint
20.2.4.5. Strategy Overview
20.2.4.5.1. Marketing Strategy
20.2.4.5.2. Product Strategy
20.2.4.5.3. Channel Strategy
20.2.5. Bio Rad Laboratories Inc
20.2.5.1. Overview
20.2.5.2. Product Portfolio
20.2.5.3. Profitability by Market Segments (Product/Channel/Region)
20.2.5.4. Sales Footprint
20.2.5.5. Strategy Overview
20.2.5.5.1. Marketing Strategy
20.2.5.5.2. Product Strategy
20.2.5.5.3. Channel Strategy
20.2.6. GE Healthcare
20.2.6.1. Overview
20.2.6.2. Product Portfolio
20.2.6.3. Profitability by Market Segments (Product/Channel/Region)
20.2.6.4. Sales Footprint
20.2.6.5. Strategy Overview
20.2.6.5.1. Marketing Strategy
20.2.6.5.2. Product Strategy
20.2.6.5.3. Channel Strategy
20.2.7. Illumina, Inc
20.2.7.1. Overview
20.2.7.2. Product Portfolio
20.2.7.3. Profitability by Market Segments (Product/Channel/Region)
20.2.7.4. Sales Footprint
20.2.7.5. Strategy Overview
20.2.7.5.1. Marketing Strategy
20.2.7.5.2. Product Strategy
20.2.7.5.3. Channel Strategy
20.2.8. Koninklijke Philips N.V.
20.2.8.1. Overview
20.2.8.2. Product Portfolio
20.2.8.3. Profitability by Market Segments (Product/Channel/Region)
20.2.8.4. Sales Footprint
20.2.8.5. Strategy Overview
20.2.8.5.1. Marketing Strategy
20.2.8.5.2. Product Strategy
20.2.8.5.3. Channel Strategy
20.2.9. Toshiba Medical Systems Corporation
20.2.9.1. Overview
20.2.9.2. Product Portfolio
20.2.9.3. Profitability by Market Segments (Product/Channel/Region)
20.2.9.4. Sales Footprint
20.2.9.5. Strategy Overview
20.2.9.5.1. Marketing Strategy
20.2.9.5.2. Product Strategy
20.2.9.5.3. Channel Strategy
20.2.10. Agilent Technologies, Inc.
20.2.10.1. Overview
20.2.10.2. Product Portfolio
20.2.10.3. Profitability by Market Segments (Product/Channel/Region)
20.2.10.4. Sales Footprint
20.2.10.5. Strategy Overview
20.2.10.5.1. Marketing Strategy
20.2.10.5.2. Product Strategy
20.2.10.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Test Type
Table 02: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 03: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 04: Global Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Region
Table 05: North America Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 06: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 07: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 08: North America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 09: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 10: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 11: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 12: Latin America Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 13: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 14: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 15: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 16: Europe Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 17: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 18: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 19: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 20: South Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 21: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 22: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 23: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 24: East Asia Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 25: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 26: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 27: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 28: Oceania Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 29: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 30: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 31: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 32: MEA Cancer Diagnostics Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 02: Global Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 03: Global Cancer Diagnostics Market Absolute $ Opportunity, 2021 - 2031
Figure 04: Global Cancer Diagnostics Market Share Analysis (%),By Test Type, 2021-2031
Figure 05: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By Test Type, 2021-2031
Figure 06: Global Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 07: Global Cancer Diagnostics Market Share Analysis (%), By Indication, 2021-2031
Figure 08: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By Indication, 2021-2031
Figure 09: Global Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 10: Global Cancer Diagnostics Market Share Analysis (%), By End User, 2021-2031
Figure 11: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By End User, 2021-2031
Figure 12: Global Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 13: Global Cancer Diagnostics Market Share Analysis (%), By Region, 2021-2031
Figure 14: Global Cancer Diagnostics Market Y-o-Y Analysis (%), By Region, 2021-2031
Figure 15: Global Cancer Diagnostics Market Attractiveness Analysis by Region, 2021-2031
Figure 16: North America Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 17: North America Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 18: North America Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 19: North America Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 20: North America Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 21: North America Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 22: North America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 23: North America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 24: North America Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 25: North America Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 26: Latin America Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 27: Latin America Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 28: Latin America Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 29: Latin America Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 30: Latin America Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 31: Latin America Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 32: Latin America Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 33: Latin America Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 34: Latin America Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 35: Latin America Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 36: Europe Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 37: Europe Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 38: Europe Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 39: Europe Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 40: Europe Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 41: Europe Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 42: Europe Cancer Diagnostics Market Attractiveness Analysis By Test Type , 2021-2031
Figure 43: Europe Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 44: Europe Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 45: Europe Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 46: South Asia Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 47: South Asia Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 48: South Asia Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 49: South Asia Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 50: South Asia Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 51: South Asia Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 52: South Asia Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 53: South Asia Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 54: South Asia Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 55: South Asia Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 56: East Asia Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 57: East Asia Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 58: East Asia Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 59: East Asia Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 60: East Asia Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 61: East Asia Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 62: East Asia Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 63: East Asia Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 64: East Asia Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 65: East Asia Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 66: Oceania Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 67: Oceania Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 68: Oceania Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 69: Oceania Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 70: Oceania Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 71: Oceania Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 72: Oceania Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 73: Oceania Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 74: Oceania Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 75: Oceania Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 76: MEA Cancer Diagnostics Market Value Share, By Test Type, 2020 (E)
Figure 77: MEA Cancer Diagnostics Market Value Share, By Indication, 2020 (E)
Figure 78: MEA Cancer Diagnostics Market Value Share, By End User, 2020 (E)
Figure 79: MEA Cancer Diagnostics Market Value Share, By Country, 2020 (E)
Figure 80: MEA Cancer Diagnostics Market Value Analysis (US$ Mn), 2016-2020
Figure 81: MEA Cancer Diagnostics Market Value Forecast (US$ Mn), 2021-2031
Figure 82: MEA Cancer Diagnostics Market Attractiveness Analysis By Test Type, 2021-2031
Figure 83: MEA Cancer Diagnostics Market Attractiveness Analysis By Indication, 2021-2031
Figure 84: MEA Cancer Diagnostics Market Attractiveness Analysis by End User, 2021-2031
Figure 85: MEA Cancer Diagnostics Market Attractiveness Analysis by Country, 2021-2031
Figure 86: U.S. Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 87: U.S. Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 88: U.S. Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 89: North America Vs. U.S. Growth Comparison
Figure 90: Canada Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 91: Canada Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 92: Canada Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 93: North America Vs. Canada Growth Comparison
Figure 94: Brazil Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 95: Brazil Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 96: Brazil Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 97: Latin America Vs. Brazil Growth Comparison
Figure 98: Mexico Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 99: Mexico Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 100: Mexico Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 101: Latin America Vs. Mexico Growth Comparison
Figure 102: Argentina Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 103: Argentina Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 104: Argentina Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 105: Latin America Vs. Argentina Growth Comparison
Figure 106: U.K. Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 107: U.K. Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 108: U.K. Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 109: Europe Vs. U.K. Growth Comparison
Figure 110: Germany Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 111: Germany Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 112: Germany Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 113: Europe Vs. Germany Growth Comparison
Figure 114: Italy Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 115: Italy Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 116: Italy Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 117: Europe Vs. Italy Growth Comparison
Figure 118: France Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 119: France Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 120: France Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 121: Europe Vs. France Growth Comparison
Figure 122: Spain Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 123: Spain Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 124: Spain Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 125: Europe Vs. Spain Growth Comparison
Figure 126: Russia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 127: Russia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 128: Russia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 129: Europe Vs. Russia Growth Comparison
Figure 130: India Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 131: India Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 132: India Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 133: South Asia Vs. India Growth Comparison
Figure 134: Thailand Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 135: Thailand Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 136: Thailand Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 137: South Asia Vs. Thailand Growth Comparison
Figure 138: Malaysia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 139: Malaysia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 140: Malaysia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 141: South Asia Vs. Malaysia Growth Comparison
Figure 142: Indonesia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 143: Indonesia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 144: Indonesia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 145: South Asia Vs. Indonesia Growth Comparison
Figure 146: China Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 147: China Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 148: China Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 149: East Asia Vs. China Growth Comparison
Figure 150: Japan Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 151: Japan Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 152: Japan Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 153: East Asia Vs. Japan Growth Comparison
Figure 154: South Korea Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 155: South Korea Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 156: South Korea Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 157: East Asia Vs. South Korea Growth Comparison
Figure 158: Australia Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 159: Australia Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 160: Australia Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 161: Oceania Vs. Australia Growth Comparison
Figure 162: New Zealand Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 163: New Zealand Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 164: New Zealand Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 165: Oceania Vs. New Zealand Growth Comparison
Figure 166: Turkey Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 167: Turkey Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 168: Turkey Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 169: MEA Vs. Turkey Growth Comparison
Figure 170: GCC Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 171: GCC Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 172: GCC Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 173: MEA Vs. GCC Growth Comparison
Figure 174: South Africa Cancer Diagnostics Market Share Analysis (%), By Test Type, 2021 & 2031
Figure 175: South Africa Cancer Diagnostics Market Share Analysis (%), By Indication, 2021 & 2031
Figure 176: South Africa Cancer Diagnostics Market Share Analysis (%), By End Users, 2021 & 2031
Figure 177: MEA Vs. South Africa Growth Comparison
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
